MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

CANNANNEW REPORT

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022 BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. Food and Drug Administration clearance of its Investigational New Drug (IND) application for the Phase 2 trial of MYMD-1 as a therapy for delaying aging and prolonging healthy lifespan. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To our knowledge, ours is the only IND application ever accepted by the FDA for a Phase 2 trial of a patented drug that seeks to delay aging. While there are other TNF-alpha, IL-6 and IL-17 blockers on the market, they are used for other indications; those drugs are not approved by the FDA for treating aging, frailty, and sarcopenia (loss of muscle tissue),” explained Chris Chapman, M.D., President, Director and Chief Medical Officer of MyMD. “Our treatment designed for delaying aging has a distinctive drug profile of oral delivery, selectivity, and very low toxicity as compared with TNF blockers, all of which are delivered by injection only. “MYMD-1 is designed to become the first and only FDA-approved therapeutic solution for delaying aging and prolonging healthspan—i.e. years of life with minimized chronic disease and maximized good health,” Dr. Chapman continued. “For multiple health and safety reasons, we believe orally dosed MYMD-1 is vastly superior to any of the available TNF inhibitors on the market today, one of which is the best-selling drug in the world.” As cleared…

Excerpt only …
READ MORE BELOW
Source : MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.